Insight, China's Pharmaceutical Industry

Company Deals

BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced a multifaceted collaboration agreement with...

Company Drug

BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities

Fineline Cube Aug 11, 2026

BeOne Medicines Ltd. (NASDAQ: ONC; HKG: 6160; SHA: 688235) announced that Imdelltra (tarlatamab for injection)...

Company Deals

Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL

Fineline Cube Aug 11, 2026

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting‑edge...

Company Drug

Astellas Submits NDA in Japan for Fezolinetant, a First-in-Class Nonhormonal NK3 Receptor Antagonist for Menopausal Vasomotor Symptoms

Fineline Cube Aug 11, 2026

Astellas Pharma Inc. (TYO: 4503) announced that it has submitted a New Drug Application (NDA)...

Company Deals

Xtalpi and Gan & Lee Pharmaceuticals’ AI Peptide Delivery Lab Recognized as Beijing Key Laboratory, Deepening AI‑Powered Peptide Drug R&D Collaboration

Fineline Cube Aug 11, 2026

XtalPi Inc. (HKG: 2228) and Gan & Lee Pharmaceuticals (SHA: 603087) announced that their jointly...

Others

CrystalO Biopharma Signs Collaboration and Licensing Deal With Almirall for AI‑Driven Skin Disease Drug Discovery, Worth Up to €254.5 Million

Fineline Cube Aug 11, 2026

CrystalO Biopharma Co., Ltd. announced that it has entered into a collaboration and licensing agreement...

Company Deals

Tonghua Golden‑Horse Unit Signs M&A Intent Agreement to Acquire Controlling Stake in 8PLUS1 Pharma

Fineline Cube Aug 11, 2026

Guilin Golden-Horse Innovation Investment Co., Ltd., a wholly owned subsidiary of Tonghua Golden-Horse Pharmaceutical Industry...

Company Deals

Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases

Fineline Cube Aug 11, 2026

Xinno Biotechnology (Jiashan) Co., Ltd. announced an exclusive technology collaboration agreement with US‑based Statia Biopharma,...

Others

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Fineline Cube Aug 10, 2026

The Joint Procurement Office published the official winning results for the 12th batch of National...

Company Medical Device

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Fineline Cube Aug 10, 2026

Sino Medical Sciences Technology Inc. (SHA: 688108) announced that the COMETIU self‑expanding intracranial drug‑eluting stent...

Company Deals

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Fineline Cube Aug 10, 2026

Hopstem Biotechnology announced the completion of the first close of its nearly RMB 200 million...

Company Drug

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Fineline Cube Aug 10, 2026

Huadong Medicine (SHE: 000963) announced that KIO015 — a novel, patented carboxymethyl chitosan solution for...

Company Deals

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Fineline Cube Aug 10, 2026

Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary...

Company Deals

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

Fineline Cube Aug 10, 2026

Kelun-Biotech (HKG: 6990) announced a strategic commercialization agreement with New Frontier Health Technology, a subsidiary...

Company Drug

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Fineline Cube Aug 10, 2026

GenFleet Therapeutics (HKG: 2595) announced that “Kylin‑Flight 01,” the registrational Phase 3 clinical trial of...

Company Deals

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

Fineline Cube Aug 10, 2026

Braveheart Bio (NASDAQ: BRVE), a partner of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG:...

Legal / IP

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Fineline Cube Aug 10, 2026

WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) announced that the U.S. District Court for the District...

Company Drug

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Fineline Cube Aug 10, 2026

Salubris Pharmaceuticals (SHE: 002294) announced that its self‑developed innovative siRNA drug SAL0195 has been approved by...

Company Drug

Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis

Fineline Cube Aug 10, 2026

Grand Pharmaceutical Group Limited (HKG: 0512) announced that GPN01530-2, a global innovative radionuclide drug conjugate (RDC)...

Company Drug

Alebund’s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients

Fineline Cube Aug 10, 2026

Alebund Pharmaceuticals (Jiangsu) Limited (HKG: 9637) announced that the New Drug Application (NDA) for its core...

Insight, China's Pharmaceutical Industry

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

BeOne Medicines and Revolution Medicines Announce Clinical Collaboration and Regional Licensing Deal on RAS(ON) Inhibitors Across Select Asian Markets

BeOne Medicines Announces Imdelltra (Tarlatamab), First-in-Class DLL3/CD3 T-Cell Engager Co-Developed With Amgen, Enters Clinical Use Across 17 Chinese Cities

Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL

Astellas Submits NDA in Japan for Fezolinetant, a First-in-Class Nonhormonal NK3 Receptor Antagonist for Menopausal Vasomotor Symptoms

Xtalpi and Gan & Lee Pharmaceuticals’ AI Peptide Delivery Lab Recognized as Beijing Key Laboratory, Deepening AI‑Powered Peptide Drug R&D Collaboration

CrystalO Biopharma Signs Collaboration and Licensing Deal With Almirall for AI‑Driven Skin Disease Drug Discovery, Worth Up to €254.5 Million

Tonghua Golden‑Horse Unit Signs M&A Intent Agreement to Acquire Controlling Stake in 8PLUS1 Pharma

Xinno Biotechnology and Statia Biopharma Sign Exclusive Deal to Develop STA528 Transdermal Therapy for Autoimmune Diseases

China’s 12th National VBP Round Officially Confirmed: 490 Enterprises Selected as Planned Procurement Value Shrinks Over One‑Third to RMB 19.5 Billion

Sino Medical Sciences’ Neurovita Wins EU MDR CE Certification for COMETIU, World’s First Intracranial Drug‑Eluting Stent System

Hopstem Biotech Completes First Close of Nearly RMB 200 Million Series C to Advance iPSC Cell Therapy Pipeline Led by hNPC01

Huadong Medicine’s Sinclair Secures EU MDR CE Certification for KIO015 Chitosan Skin Booster Kytogen Defend

Recursion and Roche‑Genentech Reach First Validated Target Milestone in USD 12 Billion AI Drug Discovery Alliance

Kelun-Biotech Signs Commercialization Deal With New Frontier Health for Sacituzumab Tirumotecan in Hong Kong and Macao

GenFleet Therapeutics Initiates Phase 3 Trial of GFH375 for KRAS G12D‑Mutant NSCLC in China, First Patient Enrolled

Braveheart Bio, Hengrui Pharma Partner, Debuts on NASDAQ With USD 439.9 Million IPO Powered by HRS‑1893 Cardiac Myosin Inhibitor

WuXi AppTec Wins Preliminary Injunction Against DoD 1260H Designation

Salubris’s SAL0195 siRNA Drug Wins NMPA Nod for Lp(a) Clinical Trials

Grand Pharma’s GPN01530-2 RDC Drug Snags FDA Fast Track for Solid Tumor Diagnosis

Alebund’s AP301 NDA Accepted by NMPA for Hyperphosphatemia in CKD Dialysis Patients

You Missed

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate